NCT04136275View on ClinicalTrials.gov

CAR-37 T Cells in Hematologic Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 19, 2020

Primary Completion Date

September 30, 2023

Study Completion Date

March 1, 2024

Conditions
Hematologic MalignancyLeukemiaLymphomaLymphoma, B-CellLymphoma, T-CellLymphoma, Non-Hodgkin
Interventions
BIOLOGICAL

CAR-37 T cells

CAR-37 is an investigational treatment that uses the participant own immune cells, called T cells, to try to kill the cancerous cells

Trial Locations (1)

02114

Massachusetts General Hospital Cancer Center, Boston

All Listed Sponsors
lead

Marcela V. Maus, M.D.,Ph.D.

OTHER

NCT04136275 - CAR-37 T Cells in Hematologic Malignancies | Biotech Hunter | Biotech Hunter